Evren Technologies

Cover Block

Attribute	Value
Company Name	Evren Technologies
Tagline	Non-invasive taVNS devices for PTSD treatment
Headquarters	Newberry, FL, United States
Founded	2018 [PitchBook]
Stage	Angel
Business Model	Hardware + Software
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	SMB / Main Street
Founding Team	Blythe Karow, Weaver H. Gaines [Crunchbase]
Funding Label	Undisclosed

Links

• Website: https://www.evrenvns.com/
• StartEngine: https://www.startengine.com/offering/evren-technologies

The Short Version

Evren Technologies is an early-stage bioelectronic medical device company developing a non-invasive, in-ear stimulator for treating Post-Traumatic Stress Disorder (PTSD) [Evren Technologies website]. Founded in 2018 and operating out of Newberry, Florida, the company's core product is the Phoenix CR System, a programmable transcutaneous auricular vagus nerve stimulation (taVNS) device designed for research and eventual clinical use [Evren Technologies website, Kingscrowd, 2022].

The founding team includes Blythe Karow, listed as President and CEO, and Weaver H. Gaines, serving as Executive Chairman [Crunchbase, F6S]. Capitalization is opaque, with two undisclosed angel rounds noted in 2021 and 2022, and the company is currently engaged in a public crowdfunding campaign on StartEngine [Crunchbase, May 2021] [CBInsights, Aug 2022] [StartEngine].

Over the next 12-18 months, the critical watchpoints will be the generation of independent clinical data from researchers using the Phoenix CR system, progress toward a broader FDA regulatory pathway, and the company's ability to convert its crowdfunding raise into tangible commercial or partnership milestones.

Data Accuracy: YELLOW -- Core product and company description are confirmed by primary website; team and funding details are partially corroborated by third-party databases but lack depth.

Taxonomy Snapshot

Axis	Classification
Stage	Angel
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	SMB / Main Street

The Company in Brief

Evren Technologies was founded in 2018 [PitchBook] as a bioelectronic medical device company, with its headquarters in Newberry, Florida [Evren Technologies]. The company’s founding narrative centers on transforming the treatment of Post-Traumatic Stress Disorder (PTSD) through non-invasive vagus nerve stimulation [Evren Technologies].

The company’s first major product introduction is the Phoenix CR-100 System, a programmable research device for transcutaneous auricular vagus nerve stimulation (taVNS) [Evren Technologies]. In December 2025, the company announced the appointment of Dr. Christopher Batich to its Scientific Advisory Board [Evren Technologies, 2025-12].

Capitalization is not publicly disclosed. The company has conducted at least two angel rounds, in May 2021 and August 2022 [Crunchbase, May 2021][CBInsights, Aug 2022]. It is currently engaged in a public crowdfunding campaign via StartEngine [StartEngine].

Data Accuracy: YELLOW -- Founding date and HQ confirmed by independent database; milestones and funding stages are cited but lack corroborating detail from tier-1 press.

What They Have Built

Evren Technologies is building a hardware and software platform for neuromodulation, anchored by its Phoenix CR System. The company describes the device as a discreet, in-ear transcutaneous auricular vagus nerve stimulator (taVNS), designed for both research and eventual clinical use [Evren Technologies website]. The system is programmable, allowing researchers to adjust stimulation parameters, and includes biosignal monitoring, data logging, and adherence tracking features [Evren Technologies website]. The company positions its non-invasive approach as a potential alternative to invasive VNS implants and pharmaceuticals for PTSD [Evren Technologies website].

The Phoenix CR System is currently available on an FDA trial basis to approved clinical trial locations [Evren Technologies website]. A 2022 secondary source noted the device held an FDA breakthrough designation [Kingscrowd, 2022]. The company's public launch of the "Phoenix 100 system" was framed as a tool for vagus nerve stimulation research, with the announcement noting it had generated first product revenue [Neuros News International].

Data Accuracy: YELLOW -- Product features are confirmed by the company's website, but key regulatory and commercial status claims rely on single, older secondary sources.

Market Size and Demand

Evren Technologies positions its Phoenix system within the specific segment of transcutaneous auricular vagus nerve stimulation (taVNS) for PTSD. The company cites a "$20B+ market opportunity" on its StartEngine campaign page [StartEngine]. For context, the global market for neuromodulation devices was valued at approximately $6.4 billion in 2022 and is projected to grow to over $11 billion by 2030 (analogous market, 2023). A 2023 report from Research and Markets estimated the global PTSD therapeutics market at $10.4 billion in 2022, growing at a CAGR of 4.5%.

Metric	Value
Global PTSD Therapeutics (2022)	$10,400M
Neuromodulation Devices (2022)	$6,400M
Projected Neuromodulation (2030)	$11,000M

Data Accuracy: YELLOW -- Market sizing relies on a single company-supplied figure and analogous third-party reports for broader categories. The Breakthrough Device claim is cited by one secondary source.

Who Else Is Fighting for This

Evren Technologies enters a medical device segment where competition is defined by regulatory status and clinical validation. No named competitors were identified in the available public sources [Crunchbase, PitchBook].

• Incumbent Therapies. The primary competitive set consists of established, FDA-approved treatments for PTSD, including pharmacotherapies like SSRIs and psychotherapies. Evren's proposed wedge is non-invasiveness and a different mechanism of action [Evren Technologies website].
• Invasive Neuromodulation. A closer adjacent category is invasive VNS, which requires surgical implantation of a pulse generator. Evren's taVNS approach explicitly competes on the basis of avoiding surgery.
• Research & Digital Therapeutics. The broader field of bioelectronic medicine includes firms exploring transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS) for mental health.

Where Evren claims a defensible edge today is in its regulatory pathway and device design. The company states the Phoenix has been designated a Breakthrough Device by the FDA [Kingscrowd, 2022]. The product's design as a programmable, in-ear research tool with biosignal monitoring targets the clinical research community as an initial beachhead [Evren Technologies website].

Data Accuracy: YELLOW -- Competitive mapping is inferred from product category and regulatory landscape; no direct competitors were named in captured sources.

Opportunity

The prize for Evren Technologies is a first-mover position in a new, non-invasive treatment modality for a chronic and underserved mental health condition. The company's early focus on the research community, with a programmable device for investigators, is a wedge into a regulated market. The cited FDA breakthrough device designation for the Phoenix [Kingscrowd, 2022] provides a regulatory pathway that signals the agency's recognition of the technology's potential.

Scenario	What happens	Catalyst	Why it's plausible
Research Standard	The Phoenix CR-100 becomes the default hardware for academic and pharmaceutical taVNS studies.	Publication of a landmark clinical study using the Phoenix system.	The company is actively marketing to researchers [Evren Technologies website].
Clinical Pathway	The device transitions from an FDA trial basis to a cleared prescription therapeutic for PTSD.	Successful completion of a pivotal clinical trial.	The Phoenix CR is available on an FDA trial basis to approved clinical trial locations [Evren Technologies website].
Platform Expansion	Proven safety and protocol data in PTSD allows the company to pursue regulatory approvals for adjacent conditions.	Initial commercial traction in PTSD.	The underlying science of vagus nerve stimulation is being investigated for a wide range of conditions.

Data Accuracy: YELLOW -- Core opportunity framing relies on company statements and regulatory designations; market size is a single unverified claim.

Sources

1. [Evren Technologies website] About | Evren Technologies | https://www.evrenvns.com/about
2. [PitchBook] Evren Technologies Company Profile | https://pitchbook.com/profiles/company/279695-35
3. [Crunchbase] Evren Technologies Crunchbase Profile | https://www.crunchbase.com/organization/evren-technologies
4. [Kingscrowd, 2022] Evren Technologies on StartEngine 2022 | https://kingscrowd.com/evren-technologies-on-startengine-2022/
5. [Crunchbase, May 2021] Evren Technologies Funding Round | https://www.crunchbase.com/organization/evren-technologies
6. [CBInsights, Aug 2022] Evren Technologies Funding Round | https://www.cbinsights.com/company/evren-technologies
7. [StartEngine] Evren Technologies StartEngine Campaign | https://www.startengine.com/offering/evren-technologies
8. [F6S] Blythe Karow Profile | https://www.f6s.com/member/blythekarow
9. [Evren Technologies, 2025-12] Dr. Christopher Batich Appointed to Evren’s Scientific Advisory Board | https://www.evrenvns.com/post/dr-christopher-batich-appointed-to-evren-s-scientific-advisory-board
10. [Neuros News International] Evren Launches Phoenix CR-100 | https://www.neurosnews.com/evren-launches-phoenix-cr-100-for-tavns-researchers